Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Maze Therapeutics, Inc. - Common Stock
(NQ:
MAZE
)
25.40
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
25.40
Bid (Size)
23.40 (100)
Ask (Size)
28.00 (1,000)
Prev. Close
25.40
Today's Range
25.40 - 25.40
52wk Range
9.830 - 53.65
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
May 27, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
↗
May 17, 2026
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.
Via
The Motley Fool
Performance
YTD
-36.1%
-36.1%
1 Month
-4.4%
-4.4%
3 Month
-43.9%
-43.9%
6 Month
-40.4%
-40.4%
1 Year
+83.1%
+83.1%
More News
Read More
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
May 12, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials
↗
May 07, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Maze Therapeutics Announces $150 Million Registered Offering
April 22, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
↗
April 04, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
March 25, 2026
Via
Chartmill
Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%
↗
March 25, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Wednesday's session: top gainers and losers
↗
March 25, 2026
Via
Chartmill
Which stocks are gapping on Wednesday?
↗
March 25, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
March 25, 2026
Via
Chartmill
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
March 25, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
March 25, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears
↗
March 21, 2026
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing
↗
February 18, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge
↗
February 16, 2026
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock
↗
February 01, 2026
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150%
↗
January 07, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
↗
December 08, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 06, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
November 06, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Maze Therapeutics to Participate in Four Upcoming Investor Conferences
November 04, 2025
From
Maze Therapeutics, Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Maze Therapeutics, Inc. - Common Stock publicly traded?
Yes, Maze Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Maze Therapeutics, Inc. - Common Stock trade on?
Maze Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Maze Therapeutics, Inc. - Common Stock?
The ticker symbol for Maze Therapeutics, Inc. - Common Stock is MAZE on the Nasdaq Stock Market
What is the current price of Maze Therapeutics, Inc. - Common Stock?
The current price of Maze Therapeutics, Inc. - Common Stock is 25.40
When was Maze Therapeutics, Inc. - Common Stock last traded?
The last trade of Maze Therapeutics, Inc. - Common Stock was at 06/04/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
